Severe hemorrhage can become a time-critical medical emergency because substantial blood loss can reduce circulating volume and restrict blood flow to vital organs. Maternal hemorrhage presents a particularly urgent scenario. Cleveland Clinic describes postpartum hemorrhage as severe bleeding after childbirth that can cause a sharp drop in blood pressure and, in serious cases, hypovolemic shock. The organization notes that prompt treatment is important because blood loss can progress rapidly.
For Miroslav Mašata, CEO and founder of P4P Technology, a Czech biotechnology company researching plant-derived Edestin for potential intravenous applications, this clinical reality raises a broader scientific question: What happens when the ideal blood product is not immediately available?
The question begins with understanding the functions being lost during hemorrhage. According to material indexed by ScienceDirect, plasma is the liquid component of blood and consists of approximately 90% water, with proteins, ions, nutrients, and gases making up the remainder. The material identifies albumin as the most prominent plasma protein, with a role in maintaining blood’s osmotic pressure and transporting various substances.
Those functions help explain why emergency volume replacement presents a distinct scientific problem. Blood products involve considerations including compatibility, collection, storage, transportation, and availability. A 2026 review published by Taylor & Francis also describes the temperature-control and transportation requirements associated with blood components. When blood products require additional time to obtain, clinicians may use intravenous fluids as part of emergency management, depending on the circumstances. Cleveland Clinic, for example, lists IV fluids and blood transfusion among treatments that may be used for postpartum hemorrhage.
This creates the intellectual question at the center of P4P’s research: restoring circulating volume represents one physiological objective, while reproducing the complete biological functions of blood represents a much broader undertaking. Mašata emphasizes that blood cells, plasma proteins, clotting factors, immune components, and other elements each contribute different functions. For him, that distinction suggests a research pathway focused on individual physiological requirements.
“Blood is an extraordinarily complex biological system,” Mašata says. “The scientific opportunity may be to identify which functions matter most in a particular emergency and investigate whether biotechnology can support those functions through a material that can be developed, manufactured, and evaluated independently.”
P4P Technology is investigating Edestin, a plant-derived globular protein, as a potential material for blood-volume expansion. According to Mašata, development requires investigation of factors including circulating-volume maintenance, oncotic pressure, pH, osmolality, toxicity, kidney compatibility, physiological effects, and potential mutagenic concerns. These represent research and validation criteria, with clinical suitability remaining subject to further evidence.
Maternal hemorrhage gives the research a more specific emergency context. The World Health Organization’s consolidated guidelines for postpartum hemorrhage emphasize evidence-based diagnosis and treatment, alongside preparation involving healthcare workers, procurement, distribution, and emergency-response capacity. WHO’s 2026 reporting also notes continuing differences in access to safe blood and blood products between healthcare systems and countries.
Maternal hemorrhage is particularly relevant to this research question because blood loss can develop rapidly around childbirth. Cleveland Clinic estimates postpartum hemorrhage occurs in approximately 1% to 5% of deliveries and explains that significant blood loss can reduce blood flow to organs including the heart, brain, liver, and kidneys.
P4P’s proposed maternal hemorrhage pathway focuses specifically on the volume loss component of this emergency. Mašata states, “We have plans for further animal research to investigate questions such as how much circulating volume could potentially be replaced, how rapidly an investigational solution could be administered, and how the body responds under controlled blood-loss conditions.” He notes that animal research at this stage is intended to help determine whether the concept warrants progression toward human clinical research.
Mašata uses a reference to the Fallout series to illustrate the appeal of a compact emergency intervention. “In the games, a Stimpak is presented as a handheld device used to help stabilize an injured character,” he explains. “The real-world development of an intravenous biological material involves a much longer scientific process.” For P4P Technology, that process includes investigating factors such as purity, formulation, toxicity, physiological compatibility, dosage, administration rate, organ effects, and performance in relevant preclinical models. Each stage is intended to generate evidence that can inform the next, with human clinical research and regulatory evaluation remaining subsequent steps in determining whether the concept has a place in medical practice.
For Mašata, this progression from concept to evidence is fundamental. “The important question is not simply whether Edestin has interesting biological characteristics,” he says. “Those characteristics have to be examined through safety studies, formulation work, dosage research, animal testing, clinical trials, manufacturing controls, and regulatory review.”
That framework also leaves open potential applications beyond maternal hemorrhage. If future research establishes an appropriate safety and efficacy profile, selected volume-expansion uses could potentially be investigated in trauma care, disaster medicine, remote healthcare, or other circumstances where access to blood products may be constrained. Each application would require its own evidence base and regulatory assessment.
Ultimately, the broader proposition is a research question about whether biotechnology can make selected physiological functions more scalable and deployable. P4P Technology’s Edestin program represents an investigation into that possibility, with maternal hemorrhage providing a highly specific setting in which rapid volume loss makes the question particularly relevant.
“The goal is to give science a question that can be tested,” Mašata says. “If the evidence supports the concept, the next questions become clinical and regulatory. That evidence has to determine where the technology belongs.”
For emergency medicine, the longer-term question may be whether biotechnology can provide additional tools when time, blood availability, and access create practical constraints. For P4P Technology, the next stage remains evidence: testing the material, defining its physiological limits, establishing safety, and determining through regulatory and clinical evaluation whether Edestin can contribute to selected aspects of emergency volume replacement.
